AstraZeneca injects $2 billion into Summit Therapeutics to fund ivonescimab development
AstraZeneca completed a $2.0 billion investment in Summit Therapeutics, its partner developing the bispecific antibody ivonescimab. The funding was announced alongside Summit’s third‑quarter update, which highlighted statistically significant overall‑survival results for ivonescimab in advanced NSCLC and biliary‑tract cancer. The U.S. FDA has set a PDUFA goal date of 14 November 2026 for Summit’s pending biologics license application. Summit also reported cash and investments of $629.8 million for the quarter.
Why it matters
The capital infusion strengthens Summit’s balance sheet and supports ongoing Phase III trials, potentially accelerating a market launch if the FDA grants approval. The FDA’s November 2026 goal date gives investors a clear timeline for a regulatory decision.
Key facts
- 1AstraZeneca invested $2.0 billion in Summit Therapeutics. stocktitan.net
- 2The $2.0 billion investment was completed as reported in Summit’s Q3 update. tradingview.com
- 3The FDA set a PDUFA goal action date of 14 November 2026 for Summit’s biologics license application for ivonescimab. stocktitan.net
- 4The FDA goal date of 14 November 2026 was also noted in Summit’s Q3 filing. tradingview.com
- 5Summit reported cash and investments of $629.8 million for the third quarter. tradingview.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.